News – Page 1088 – Endpoints News

SIGN UP

#ESMO17: Roche extends losing streak with a setback for Zelboraf as Novartis combo surges ahead

8 years ago

J&J scraps a multibillion-dollar hepatitis C program after rivals divvy up the market

8 years ago

#ESMO17: Bristol-Myers posts data on an upset checkpoint combo victory in frontline kidney cancer

8 years ago

#ESMO17: Eli Lilly sets the stage for a CDK 4/6 showdown with Pfizer, Novartis — but not exactly to its advantage

8 years ago

Allergan CEO gambles a multibillion-dollar franchise — and his company rep — on a high-stakes bet at an Indian ...

8 years ago

#ESMO17: AstraZeneca salves stinging setback with a big win in a blockbuster segment of the lung cancer market

8 years ago

Roche gets hit with another big R&D setback as a prospective AMD blockbuster flops in PhIII

8 years ago

Prosecutors want Shkreli thrown in jail now after Facebook threat

8 years ago

The top 5 trends reshaping biopharma starts with an R&D earthquake

8 years ago

Kura shares soar on positive PhII cancer data; M&A buzz revolves back to AstraZeneca

8 years ago

Vas Narasimhan tapped to take Novartis' helm as Joe Jimenez heads to Silicon Valley

8 years ago

Replimune adds a $55M round and some expert help as it pursues next-gen oncolytics R&D

8 years ago

#ESMO17 ROUNDUP: Merck’s data on Keytruda/chemo combo for lung cancer takes early spotlight at ESMO

8 years ago

Sanofi, Regeneron earn ‘breakthrough’ status for a fast-track drug out to prove PD-1 dominance

8 years ago

Following up on Trump's orders, the FDA wants to know: which regulations and paperwork requirements need to go?

8 years ago

Hammered by critics, NewLink strikes back with positive PhII indoximod data — and shares rocket up

8 years ago

Eli Lilly slashes R&D jobs, shutters 2 research sites as it looks to cut 3,500 staffers worldwide

8 years ago

Bristol-Myers' checkpoint combo scores in PhIII study; AstraZeneca hands Circassia positive data for COPD drug; ...

8 years ago

AbbVie adds more stellar data on ABT-494 — this time for atopic dermatitis

8 years ago

Ramping back up on oncology, GSK takes an option on Adaptimmune’s TCR cancer drug

8 years ago

Alnylam slammed after patient death forces investigators to halt dosing of fitusiran, raising new safety fears

8 years ago

Google helps boost Gritstone’s neoantigen R&D gamble to $195M as researchers prep for first human study

8 years ago

As China biotech booms, Fidelity group rolls out $250M fund with a big focus on drug R&D

8 years ago

AstraZeneca, Amgen whip up some blockbuster excitement with a possible game-changing asthma drug

8 years ago

First page Previous page 1085 1086 108710881089 1090 1091 Next page Last page